Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Michael Pendleton

Family Medicine Louisville, KY Medical Doctor

NPI 1922211556 CMS profile 674828

215 Central Ave Ste 100, Louisville, KY 40208

Open in the dashboard

General payments

$29,413

33 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Michael Pendleton of Louisville, KY is reported in the CMS Open Payments database as having received $29,413 across 33 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $2,784 4
2022 General $9,647 9
2021 General $15,540 14
2020 General $1,430 5
2019 General $13 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Pendleton
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Michael Pendleton were reported at $0. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Michael Pendleton Family Medicine median Middle half National median
2019 $13 $150 $41–$543 $163
2020 $1,430 $120 $32–$415 $114
2021 $15,540 $137 $35–$551 $132
2022 $9,647 $137 $37–$512 $149
2023 $0 $149 $42–$545 $160
2024 $2,784 $156 $44–$560 $164
2025 $0 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Organon LLC $19,651 16 payments
  2. Merck Sharp & Dohme Corporation $9,672 11 payments
  3. GlaxoSmithKline, LLC. $33 2 payments
  4. Hologic, LLC $16 1 payment
  5. Agile Therapeutics, Inc. $15 1 payment
  6. Amarin Pharma Inc. $14 1 payment
  7. Gilead Sciences, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,875 12 payments
  2. Compensation for serving as faculty or as a speaker for a medical education program $12,375 9 payments
  3. Food and Beverage $163 12 payments
Products named General payments · program years 2019–2024
  1. NEXPLANON Etonogestrel $12,401 11 payments
  2. NEXPLANON Womens Health $9,643 9 payments
  3. Nexplanon Womens Health $7,250 5 payments
  4. SHINGRIX $33 2 payments
  5. GARDASIL 9 $29 2 payments
  6. ROTATEQ $29 2 payments
  7. PNEUMOVAX 23 $29 2 payments
  8. Aptima $16 1 payment
  9. Twirla $15 1 payment
  10. VAQTA $14 1 payment
  11. Other $40 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 122 drugs

Part D claims

4,898

Median for Family Practice: 1,826

Drug cost

$315,294

Median for Family Practice: $120,094

Branded share of claims

20.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 49 $51,477
Eliquis Apixaban Brand 35 $49,795
Xarelto Rivaroxaban Brand 19 $32,362
Januvia Sitagliptin Phosphate Brand 29 $26,620
Jardiance Empagliflozin Brand 18 $26,242
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 15 $21,169
Ozempic Semaglutide Brand 16 $17,555
Trulicity Dulaglutide Brand 16 $16,377
Novolog Flexpen Insulin Aspart Brand 15 $3,697
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 22 $3,026

The 10 drugs with the highest cost, of 122 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$63,013

Of which drugs: $10,809

Medicare patients

237

Average age 73

Services billed

780

108 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 62%
Arthritis 48%
Ischemic heart disease 24%
Diabetes 21%
Chronic kidney disease 18%
Atrial fibrillation 16%
Heart failure 14%
Cancer 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 35 35 $5,250
Pcv20 vaccine im 90677 Office 13 13 $3,468
Vaccine for influenza for injection into muscle 90662 Office 24 24 $1,964

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

33 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record